secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097611
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences successful End-of-Phase 2 FDA meeting; Phase 3 trial for canvuparatide in Q3 2026
--------------------------------------------------------------------------------

- Phase 3 double-blind placebo-controlled trial will enroll ~160 patients; 3:1 randomization, 4-week fixed 600 ug dose then 18-week titration, 4-week maintenance.
- Primary endpoint: proportion of participants achieving normal serum calcium and independence from conventional therapy at Week 26; open-label extension after.
- Canvuparatide granted Orphan Drug Designation by European Medicines Agency for chronic hypoparathyroidism.
- Company on track to initiate Phase 3 trial in Q3 2026 based on FDA feedback from End-of-Phase 2 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526097611/0001193125-26-097611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526097611/mbx-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer